Lataa...
Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
The two transcription factors STAT5A and STAT5B are central signaling molecules in leukemias driven by Abelson fusion tyrosine kinases and they fulfill all criteria of drug targets. STAT5A and STAT5B display unique nuclear shuttling mechanisms and they have a key role in resistance of leukemic cells...
Tallennettuna:
| Julkaisussa: | Oncotarget |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Impact Journals LLC
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4259420/ https://ncbi.nlm.nih.gov/pubmed/25333255 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|